Summary

Genetic Testing Market By Product (Consumables, Kits and Reagents, and Software), By Testing (Nutrigenomic Testing, Pharmacogenomic Testing, Predictive Testing and Presymptomatic Testing, Prenatal and Newborn Testing, Forensic Testing, and Others), By Techniques (Polymerase chain reaction, Next-Generation Sequencing, DNA sequencing, Microarray Analysis, Others), By Disease (Alzheimer's Disease, Cystic Fibrosis, Cancer, Arrhythmias, Down syndrome, Others), and By Sample Type (Blood Sample, Saliva Sample, Tissue Sample, Other samples), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 ? 2035
The genetic Testing market accounted for USD 22.3 Billion in 2024 and is expected to reach USD 65.5 Billion by 2035, growing at a CAGR of around 10.3% between 2025 and 2035. The increasing level of healthcare awareness, the advancing technologies, and the increasing need for personalized medicine, integrated with regulatory, ethical, and cost issues affecting adoption rates, define the genetic testing market. Thus far, genetic research has been expanding the types of diseases from rare to common conditions and expanding the potential population for testing. Accessibility and affordability are still determining aspects of market penetration by geographic area. Furthermore, funding for research and development is coming from the public and private sectors. Transformations in health policy will determine the speed of adoption into clinical practice. This new competitive landscape is quite multifaceted, as mergers, collaborations, and technological innovations are reshaping the competitive landscape. Overall, the market is heading toward a more consumer-oriented, technology-driven architectural framework for the future and moving toward increased accuracy, speed, and early detection.
Rising Focus on Personalized Medicine
Treatments custom-fitted to individual genetic configurations are in demand now more than ever. Accordingly, acceptance of genetic testing is at an all-time high. Some doctors and researchers are integrating genetic information into treatment protocols so that therapies are, in effect, more efficacious and with reduced side effects. In tandem with mounting public awareness toward personalized health care options is the ongoing rise in demand for the tests. Drug companies are spending on genetic tests to advance their drug development plans. This is very much driven by the concept of preventing diseases through early intervention in personalized medicine. Clinical practice is changing to capture these tests as a routine part of diagnostics. This implies a paradigmatic move from the traditionally shared "one-size-fits-all" approach to new-age "precision health." This driver is one mainstays of sustained growth in market opportunities.
Ethical and Privacy Issues
With genetic testing looking deeply into personal biological information, privacy issues can potentially hinder the road. Safety data holders may fear discrimination based on genetic data, especially in some contexts, either employment or insurance situations. Ethical questions about consent, data retention, and ownership make it harder to accept. Nevertheless, in some parts of the world, weak legislation only heightens the risks of genetic misuse. Where a jurisdiction exists, public mistrust may prevent participation in testing programs. Furthermore, lacking an ethical guideline may put healthcare professionals on the fence about building up genetic diagnostics. All of these issues take on an even greater consumer-sensitive context in prenatal and predictive settings. Therefore, trust and transparency are pivotal barriers to address.
Expansion into Direct-to-Consumer (DTC) Testing
Health-conscious consumers propel demand for genetic testing outside mainstream health care. By direct-to-consumer models, genetic insights can be obtained without physician referrals. The convenience and freedom appeal to a wider clientele. Companies exploit this by offering easy-to-use at-home kits and digital platforms. The model also supports repeat testing and prolonged engagement through health updates and wellness encamping plans. The popularity of tests for personalized health, ancestry, and nutrition is high. As data privacy problems begin to get resolved, consumer trust in DTC testing is growing. This segment is said to have vast untapped potential for market growth.
Segment Analysis
Molecular testing is the largest sub-segment due to its accuracy and the range of diagnoses made. Cytogenetic testing mainly considers chromosomal alterations and is mostly used in the diagnosis of genetic disorders. Biochemical testing, on the other hand, is the analysis of proteins to discover metabolic disorders. Thus, the three technologies work in slightly different ways, based on the conditions being screened for. The increase in complexity of genetic diseases in some instances requires the use of more than one technology. R&D will continue to contribute further innovation across each type. Such segmentation enables service providers to provide testing solutions that are specifically tailored for certain clinical requirements.
Cancer testing is at the forefront due to increasing awareness and demand for early detection. Genetic testing for infectious diseases is a double approach of diagnosis and treatment selection. Cardiovascular genetic testing aids in the diagnosis of hereditary heart conditions, especially in younger generations. Neurological disorder testing helps in further understanding diseases such as Alzheimer's or Huntington's. Each application is being used to advance genetic insights for better outcomes and patient care. These applications are expected to coexist and expand as testing increasingly integrates into general diagnostics. Such multiplex reality adds to the market's resilience and adaptability.
Regional Analysis
North America detects the maximum mutation as the healthcare systems are advanced, and there is tremendous R&D capability. The region has favorable reimbursement policies, and the regulatory environment is pretty mature. Awareness of the consumer is at its peak, and personalized medicine is widely accepted, therefore creating demand. Frequent collaborations of academic institutions and biotech companies further propel genomics research. In contrast, the other side of the ecosystem is supported by large multinational companies. In addition, direct-to-consumer testing is attaining unlimited legitimacy, thus boosting market growth. In short, North America remains the global place of attraction for genetics testing innovation and commercialization.
Competitive Landscape
The Genetic Testing Market is highly competitive, with established players and innovative start-ups. Companies compete among themselves in technology, pricing, test accuracy, and turnaround time. Many focus on strategic collaboration with research institutions and healthcare providers to sustain a pipeline of new offerings. Innovation is continuous, with companies developing multipanel condition tests, AI-integrated platforms, and user-friendly interfaces. Mergers and acquisitions are also a popular strategy to grow capabilities and access markets. Consumer choice is significantly impacted by trust in their brand and compliance with regulations. Differentiation is increasingly through customer experience and post-test support. The competitive environment will intensify with the globalization of the market.
Report Coverage:
By Product
- Consumables
- Kits and Reagents
- Software
By Testing
- Nutrigenomic Testing
- Pharmacogenomic Testing
- Predictive Testing and Presymptomatic Testing
- Prenatal and Newborn Testing
- Forensic Testing
- Others
By Techniques
- Polymerase chain reaction
- Next-Generation Sequencing
- DNA sequencing
- Microarray Analysis
- Others
By Disease
- Alzheimer's Disease
- Cystic Fibrosis
- Cancer
- Arrhythmias
- Down syndrome
- Others
By Sample Type
- Blood Sample
- Saliva Sample
- Tissue Sample
- Other samples

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology & Report Coverage
1.1. Definition & Objective
1.2. Market Evaluation & forecast parameter
1.3. Research Methodology
1.4. Data Validation Sources
1.4.1. Secondary Research
1.4.2. Primary Research
2. Market Overview
3. Global Genetic Testing Market: Market Dynamics
3.1. Executive Summary
3.2. Market Driving Factors
3.2.1. Increasing occurrence of genetic and rare diseases is driving demand for genetic testing.
3.2.2. Shift towards personalized medicine based on genetic makeup.
3.2.3. Direct-to-consumer testing bypasses healthcare intermediaries
3.3. Key industry pitfalls & challenges
3.3.1. Insufficient infrastructure and skilled labor worldwide.
3.3.2. Ethical and societal implications of Genetic Testing.
3.3.3. Genetic test results can be complex and ambiguous.
3.4. Market Opportunities
3.4.1. The expansion of prenatal and newborn screening enhances early detection and management of genetic disorders.
3.4.2. Development of innovative Genetic Testing software.
3.4.3. Strategic partnerships drive product development and expansion.
3.5. Porter’s Five Forces Analysis
3.6. PESTLE Analysis
3.7. Regulatory landscape
3.8. Pipeline Analysis
3.9. ESG Scenario
3.10. Competitive landscape
3.10.1. Company Market Share
3.10.2. Market Positioning
3.10.3. Strategy framework
3.10.4. Recent Acquisitions & Mergers
4. Genetic Testing Market, By Product Segment Analysis
4.1. Overview Dynamics
4.1.1. Market Revenue Share, By Product, 2025 & 2035
4.1.2. Key Market Trends, Growth Factors, & Opportunities
4.2. Consumables
4.2.1. Market Size and Forecast, By 2025-2035 (USD Billion)
4.3. Kits and Reagents
4.3.1. Market Size and Forecast, By 2025-2035 (USD Billion)
4.4. Software
4.4.1. Market Size and Forecast, By 2025-2035 (USD Billion)
5. Genetic Testing Market, By Testing Segment Analysis
5.1. Overview
5.1.1. Market Revenue Share, By Testing, 2025 & 2035
5.1.2. Key Market Trends, Growth Factors, & Opportunities
5.2. Nutrigenomic Testing
5.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.3. Pharmacogenomic Testing
5.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.4. Predictive Testing and Presymptomatic Testing
5.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.5. Prenatal and Newborn Testing
5.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.6. Forensic Testing
5.6.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.7. Others
5.7.1. Market Size and Forecast, By 2025-2035(USD Billion)
6. Genetic Testing Market, By Techniques Segment Analysis
6.1. Overview
6.1.1. Market Revenue Share, By Techniques, 2025 & 2035
6.1.2. Key Market Trends, Growth Factors, & Opportunities
6.2. Polymerase chain reaction
6.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.3. Next-Generation Sequencing
6.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.4. DNA sequencing
6.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.5. Microarray Analysis
6.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.6. Others
6.6.1. Market Size and Forecast, By 2025-2035(USD Billion)
7. Genetic Testing Market, By Disease Segment Analysis
7.1. Overview
7.1.1. Market Revenue Share, By Disease, 2025 & 2035
7.1.2. Key Market Trends, Growth Factors, & Opportunities
7.2. Alzheimer's Disease
7.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.3. Cystic Fibrosis
7.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.4. Cancer
7.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.4.1 Market Size and Forecast, By 2025-2035(USD Billion)
7.5. Arrhythmias
7.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.6. Down syndrome
7.6.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.7. Others
7.7.1. Market Size and Forecast, By 2025-2035(USD Billion)
8. Genetic Testing Market, Sample Type Segment Analysis
8.1. Overview
8.1.1. Market Revenue Share, By Sample Type, 2025 & 2035
8.1.2. Key Market Trends, Growth Factors, & Opportunities
8.2. Blood Sample
8.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.3. Saliva Sample
8.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.4. Tissue Sample
8.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.5. Other samples
8.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
9. Genetic Testing Market, Region Segment Analysis
9.1. Overview
9.1.1. Global Market Revenue Share, By Region, 2025 & 2035
9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)
9.2. North America
9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)
9.2.2. North America Market Revenue, By Product, 2025-2035
9.2.3. North America Market Revenue, By Testing, 2025-2035
9.2.4. North America Market Revenue, By Techniques, 2025-2035
9.2.5. North America Market Revenue, By Disease, 2025-2035
9.2.6. North America Market Revenue, By Sample Type, 2025-2035
9.2.7. The U.S.
9.2.7.1. U.S. Market Revenue, By Product, 2025-2035
9.2.7.2. U.S. Market Revenue, By Testing, 2025-2035
9.2.7.3. U.S. Market Revenue, By Techniques, 2025-2035
9.2.7.4. U.S. Market Revenue, By Disease, 2025-2035
9.2.7.5. U.S. Market Revenue, By Sample Type, 2025-2035
9.2.8. Canada
9.2.8.1. Canada Market Revenue, By Product, 2025-2035
9.2.8.2. Canada Market Revenue, By Testing, 2025-2035
9.2.8.3. Canada Market Revenue, By Techniques, 2025-2035
9.2.8.4. Canada Market Revenue, By Disease, 2025-2035
9.2.8.5. Canada Market Revenue, By Sample Type, 2025-2035
9.3. Europe
9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)
9.3.2. Europe Market Revenue, By Product, 2025-2035
9.3.3. Europe Market Revenue, By Testing, 2025-2035
9.3.4. Europe Market Revenue, By Techniques, 2025-2035
9.3.5. Europe Market Revenue, By Disease, 2025-2035
9.3.6. Europe Market Revenue, By Sample Type, 2025-2035
9.3.7. Germany
9.3.7.1. Germany Market Revenue, By Product, 2025-2035
9.3.7.2. Germany Market Revenue, By Testing, 2025-2035
9.3.7.3. Germany Market Revenue, By Techniques, 2025-2035
9.3.7.4. Germany Market Revenue, By Disease, 2025-2035
9.3.7.5. Germany Market Revenue, By Sample Type, 2025-2035
9.3.8. France
9.3.8.1. France Market Revenue, By Product, 2025-2035
9.3.8.2. France Market Revenue, By Testing, 2025-2035
9.3.8.3. France Market Revenue, By Techniques, 2025-2035
9.3.8.4. France Market Revenue, By Disease, 2025-2035
9.3.8.5. France Market Revenue, By Sample Type, 2025-2035
9.3.9. U.K.
9.3.9.1. U.K. Market Revenue, By Product, 2025-2035
9.3.9.2. U.K. Market Revenue, By Testing, 2025-2035
9.3.9.3. U.K. Market Revenue, By Techniques, 2025-2035
9.3.9.4. U.K. Market Revenue, By Disease, 2025-2035
9.3.9.5. U.K. Market Revenue, By Sample Type, 2025-2035
9.3.10. Italy
9.3.10.1. Italy Market Revenue, By Product, 2025-2035
9.3.10.2. Italy Market Revenue, By Testing, 2025-2035
9.3.10.3. Italy Market Revenue, By Techniques, 2025-2035
9.3.10.4. Italy Market Revenue, By Disease, 2025-2035
9.3.10.5. Italy Market Revenue, By Sample Type, 2025-2035
9.3.11. Spain
9.3.11.1. Spain Market Revenue, By Product, 2025-2035
9.3.11.2. Spain Market Revenue, By Testing, 2025-2035
9.3.11.3. Spain Market Revenue, By Techniques, 2025-2035
9.3.11.4. Spain Market Revenue, By Disease, 2025-2035
9.3.11.5. Spain Market Revenue, By Sample Type, 2025-2035
9.3.12. Rest of Europe
9.3.12.1. Rest of Europe Market Revenue, By Product, 2025-2035
9.3.12.2. Rest of Europe Market Revenue, By Testing, 2025-2035
9.3.12.3. Rest of Europe Market Revenue, By Techniques, 2025-2035
9.3.12.4. Rest of Europe Market Revenue, By Disease, 2025-2035
9.3.12.5. Rest of Europe Market Revenue, By Sample Type, 2025-2035
9.4. Asia Pacific
9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)
9.4.2. Asia Pacific Market Revenue, By Product, 2025-2035
9.4.3. Asia Pacific Market Revenue, By Testing, 2025-2035
9.4.4. Asia Pacific Market Revenue, By Techniques, 2025-2035
9.4.5. Asia Pacific Market Revenue, By Disease, 2025-2035
9.4.6. Asia Pacific Market Revenue, By Sample Type, 2025-2035
9.4.7. China
9.4.7.1. China Market Revenue, By Product, 2025-2035
9.4.7.2. China Market Revenue, By Testing, 2025-2035
9.4.7.3. China Market Revenue, By Techniques, 2025-2035
9.4.7.4. China Market Revenue, By Disease, 2025-2035
9.4.7.5. China Market Revenue, By Sample Type, 2025-2035
9.4.8. Japan
9.4.8.1. Japan Market Revenue, By Product, 2025-2035
9.4.8.2. Japan Market Revenue, By Testing, 2025-2035
9.4.8.3. Japan Market Revenue, By Techniques, 2025-2035
9.4.8.4. Japan Market Revenue, By Disease, 2025-2035
9.4.8.5. Japan Market Revenue, By Sample Type, 2025-2035
9.4.9. India
9.4.9.1. India Market Revenue, By Product, 2025-2035
9.4.9.2. India Market Revenue, By Testing, 2025-2035
9.4.9.3. India Market Revenue, By Techniques, 2025-2035
9.4.9.4. India Market Revenue, By Disease, 2025-2035
9.4.9.5. India Market Revenue, By Sample Type, 2025-2035
9.4.10. Australia
9.4.10.1. Australia Market Revenue, By Product, 2025-2035
9.4.10.2. Australia Market Revenue, By Testing, 2025-2035
9.4.10.3. Australia Market Revenue, By Techniques, 2025-2035
9.4.10.4. Australia Market Revenue, By Disease, 2025-2035
9.4.10.5. Australia Market Revenue, By Sample Type, 2025-2035
9.4.11. South Korea
9.4.11.1. South Korea Market Revenue, By Product, 2025-2035
9.4.11.2. South Korea Market Revenue, By Testing, 2025-2035
9.4.11.3. South Korea Market Revenue, By Techniques, 2025-2035
9.4.11.4. South Korea Market Revenue, By Disease, 2025-2035
9.4.11.5. South Korea Market Revenue, By Sample Type, 2025-2035
9.4.12. Singapore
9.4.12.1. Singapore Market Revenue, By Product, 2025-2035
9.4.12.2. Singapore Market Revenue, By Testing, 2025-2035
9.4.12.3. Singapore Market Revenue, By Techniques, 2025-2035
9.4.12.4. Singapore Market Revenue, By Disease, 2025-2035
9.4.12.5. Singapore Market Revenue, By Sample Type, 2025-2035
9.4.13. Rest of Asia Pacific
9.4.13.1. Rest of Asia Pacific Market Revenue, By Product, 2025-2035
9.4.13.2. Rest of Asia Pacific Market Revenue, By Testing, 2025-2035
9.4.13.3. Rest of Asia Pacific Market Revenue, By Techniques, 2025-2035
9.4.13.4. Rest of Asia Pacific Market Revenue, By Disease, 2025-2035
9.4.13.5. Rest of Asia Pacific Market Revenue, By Sample Type, 2025-2035
9.5. Latin America
9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)
9.5.2. Latin America Market Revenue, By Product, 2025-2035
9.5.3. Latin America Market Revenue, By Testing, 2025-2035
9.5.4. Latin America Market Revenue, By Techniques, 2025-2035
9.5.5. Latin America Market Revenue, By Disease, 2025-2035
9.5.6. Latin America Market Revenue, By Sample Type, 2025-2035
9.5.7. Brazil
9.5.7.1. Brazil Market Revenue, By Product, 2025-2035
9.5.7.2. Brazil Market Revenue, By Testing, 2025-2035
9.5.7.3. Brazil Market Revenue, By Techniques, 2025-2035
9.5.7.4. Brazil Market Revenue, By Disease, 2025-2035
9.5.7.5. Brazil Market Revenue, By Sample Type, 2025-2035
9.5.8. Argentina
9.5.8.1. Argentina Market Revenue, By Product, 2025-2035
9.5.8.2. Argentina Market Revenue, By Testing, 2025-2035
9.5.8.3. Argentina Market Revenue, By Techniques, 2025-2035
9.5.8.4. Argentina Market Revenue, By Disease, 2025-2035
9.5.8.5. Argentina Market Revenue, By Sample Type, 2025-2035
9.5.9. Mexico
9.5.9.1. Mexico Market Revenue, By Product, 2025-2035
9.5.9.2. Mexico Market Revenue, By Testing, 2025-2035
9.5.9.3. Mexico Market Revenue, By Techniques, 2025-2035
9.5.9.4. Mexico Market Revenue, By Disease, 2025-2035
9.5.9.5. Mexico Market Revenue, By Sample Type, 2025-2035
9.5.10. Rest of Latin America
9.5.10.1. Rest of Latin America Market Revenue, By Product, 2025-2035
9.5.10.2. Rest of Latin America Revenue, By Testing, 2025-2035
9.5.10.3. Rest of Latin America Market Revenue, By Techniques, 2025-2035
9.5.10.4. Rest of Latin America Market Revenue, By Disease, 2025-2035
9.5.10.5. Rest of Latin America Market Revenue, By Sample Type, 2025-2035
9.6. MEA
9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)
9.6.2. MEA Market Revenue, By Product, 2025-2035
9.6.3. MEA Market Revenue, By Testing, 2025-2035
9.6.4. MEA Market Revenue, By Techniques, 2025-2035
9.6.5. MEA Market Revenue, By Disease, 2025-2035
9.6.6. MEA Market Revenue, By Sample Type, 2025-2035
9.6.7. GCC Countries
9.6.7.1. GCC Countries Market Revenue, By Product, 2025-2035
9.6.7.2. GCC Countries Market Revenue, By Testing, 2025-2035
9.6.7.3. GCC Countries Market Revenue, By Techniques, 2025-2035
9.6.7.4. GCC Countries Market Revenue, By Disease, 2025-2035
9.6.7.5. GCC Countries Market Revenue, By Sample Type, 2025-2035
9.6.8. South Africa
9.6.8.1. South Africa Countries Market Revenue, By Product, 2025-2035
9.6.8.2. South Africa Countries Market Revenue, By Testing, 2025-2035
9.6.8.3. South Africa Countries Market Revenue, By Techniques, 2025-2035
9.6.8.4. South Africa Countries Market Revenue, By Disease, 2025-2035
9.6.8.5. South Africa Countries Market Revenue, By Sample Type, 2025-2035
9.6.9. Rest of Middle-East Africa
9.6.9.1. Rest of Middle-East Africa Countries Market Revenue, By Product, 2025-2035
9.6.9.2. Rest of Middle-East Africa Countries Market Revenue, By Techniques, 2025-2035
9.6.9.3. Rest of Middle-East Africa Countries Market Revenue, By Technology, 2025-2035
9.6.9.4. Rest of Middle-East Africa Countries Market Revenue, By Disease, 2025-2035
9.6.9.5. Rest of Middle-East Africa Countries Market Revenue, By Sample Type, 2025-2035
10. Company Profile
10.1. MedGenome Labs Limited
10.1.1. Business Overview
10.1.2. Financial Performance
10.1.3. Product/Service Offerings
10.1.4. Strategies & recent developments
10.1.5. SWOT Analysis
10.2. Strand Life Sciences Pvt Ltd.
10.2.1. Business Overview
10.2.2. Financial Performance
10.2.3. Product/Service Offerings
10.2.4. Strategies & recent developments
10.2.5. SWOT Analysis
10.3. Centogene India Private Limited
10.3.1. Business Overview
10.3.2. Financial Performance
10.3.3. Product/Service Offerings
10.3.4. Strategies & recent developments
10.3.5. SWOT Analysis
10.4. Eurofins Genomics India Pvt Ltd.
10.4.1. Business Overview
10.4.2. Financial Performance
10.4.3. Product/Service Offerings
10.4.4. Strategies & recent developments
10.4.5. SWOT Analysis
10.5. Mapmygenome India Limited
10.5.1. Business Overview
10.5.2. Financial Performance
10.5.3. Product/Service Offerings
10.5.4. Strategies & recent developments
10.5.5. SWOT Analysis
10.6. ClevergeneBiocorp Private Limited
10.6.1. Business Overview
10.6.2. Financial Performance
10.6.3. Product/Service Offerings
10.6.4. Strategies & recent developments
10.6.5. SWOT Analysis
10.7. LifeCell International Pvt. Ltd.
10.7.1. Business Overview
10.7.2. Financial Performance
10.7.3. Product/Service Offerings
10.7.4. Strategies & recent developments
10.7.5. SWOT Analysis
10.8. Genes2Me Pvt. Ltd.
10.8.1. Business Overview
10.8.2. Financial Performance
10.8.3. Product/Service Offerings
10.8.4. Strategies & recent developments
10.8.5. SWOT Analysis
10.9. GeneTech India Private Limited
10.9.1. Business Overview
10.9.2. Financial Performance
10.9.3. Product/Service Offerings
10.9.4. Strategies & recent developments
10.9.5. SWOT Analysis
10.10. DNA Forensics Laboratory Pvt. Ltd.
10.10.1. Business Overview
10.10.2. Financial Performance
10.10.3. Product/Service Offerings
10.10.4. Strategies & recent developments
10.10.5. SWOT Analysis
10.11. Lilac Insights
10.11.1. Business Overview
10.11.2. Financial Performance
10.11.3. Product/Service Offerings
10.11.4. Strategies & recent developments
10.11.5. SWOT Analysis
10.12. Xcode Life
10.12.1. Business Overview
10.12.2. Financial Performance
10.12.3. Product/Service Offerings
10.12.4. Strategies & recent developments
10.12.5. SWOT Analysis
10.13. Positive Bioscience
10.13.1. Business Overview
10.13.2. Financial Performance
10.13.3. Product/Service Offerings
10.13.4. Strategies & recent developments
10.13.5. SWOT Analysis
10.14. GenePath Diagnostics
10.14.1. Business Overview
10.14.2. Financial Performance
10.14.3. Product/Service Offerings
10.14.4. Strategies & recent developments
10.14.5. SWOT Analysis
10.15. Core Diagnostics
10.15.1. Business Overview
10.15.2. Financial Performance
10.15.3. Product/Service Offerings
10.15.4. Strategies & recent developments
10.15.5. SWOT Analysis

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. GLOBAL GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 2. GLOBAL GENETIC TESTING MARKET VALUE FOR ACTIVATED CARBON, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 3. GLOBAL GENETIC TESTING MARKET VALUE FOR CARBON DERIVATIVES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 4. GLOBAL GENETIC TESTING MARKET VALUE FOR METAL OXIDES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 5. GLOBAL GENETIC TESTING MARKET VALUE FOR CONDUCTIVE POLYMERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 6. GLOBAL GENETIC TESTING MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 7. GLOBAL GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 8. GLOBAL GENETIC TESTING MARKET VALUE FOR CONSUMER ELECTRONICS, 2025-2035 (USD BILLION)
TABLE 9. GLOBAL GENETIC TESTING MARKET VALUE FOR INDUSTRIAL, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 10. GLOBAL GENETIC TESTING MARKET VALUE FOR TRANSPORTATION, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 11. GLOBAL GENETIC TESTING MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 12. NORTH AMERICA GENETIC TESTING MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 13. NORTH AMERICA GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 14. NORTH AMERICA GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 15. U.S GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 16. U.S GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 17. CANADA GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 18. CANADA GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 19. EUROPE GENETIC TESTING MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 20. EUROPE GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 21. EUROPE GENETIC TESTING MARKET VALUE, APPLICATION, 2025-2035 (USD BILLION)
TABLE 22. GERMANY GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 23. GERMANY GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 24. U.K GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 25. U.K GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 26. FRANCE GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 27. FRANCE GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 28. ITALY GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 29. ITALY GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 30. SPAIN GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 31. SPAIN GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 32. ROE GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 33. ROE GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 34. ASIA PACIFIC GENETIC TESTING MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 35. ASIA PACIFIC GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 36. ASIA PACIFIC GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 37. CHINA GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 38. CHINA GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 39. INDIA GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 40. INDIA GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 41. JAPAN GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 42. JAPAN GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 43. REST OF APAC GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 44. REST OF APAC GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 45. REST OF WORLD GENETIC TESTING MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 46. REST OF WORLD GENETIC TESTING MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 47. CABOT(NORIT): FINANCIALS
TABLE 48. CABOT(NORIT): PRODUCTS & SERVICES
TABLE 49. CABOT(NORIT): RECENT DEVELOPMENTS
TABLE 50. KURARY CO. LTD: FINANCIALS
TABLE 51. KURARY CO. LTD: PRODUCTS & SERVICES
TABLE 52. KURARY CO. LTD: RECENT DEVELOPMENTS
TABLE 53. BAYER MATERIALSCIENCE AG: FINANCIALS
TABLE 54. BAYER MATERIALSCIENCE AG: PRODUCTS & SERVICES
TABLE 55. BAYER MATERIALSCIENCE AG: RECENT DEVELOPMENTS
TABLE 56. CALGON CARBON CORPORATION: FINANCIALS
TABLE 57. CALGON CARBON CORPORATION: PRODUCTS & SERVICES
TABLE 58. CALGON CARBON CORPORATION: RECENT DEVELOPMENTS
TABLE 59. CARBON NT&F: FINANCIALS
TABLE 60. CARBON NT&F: PRODUCTS & SERVICES
TABLE 61. CARBON NT&F: RECENT DEVELOPMENTS
TABLE 62. SHENZHEN NTP: FINANCIALS
TABLE 63. SHENZHEN NTP: PRODUCTS & SERVICES
TABLE 64. SHENZHEN NTP: RECENT DEVELOPMENTS
TABLE 65. CECA SA: FINANCIALS
TABLE 66. CECA SA: PRODUCTS & SERVICES
TABLE 67. CECA SA: RECENT DEVELOPMENTS
TABLE 68. CNANO TECHNOLOGY: FINANCIALS
TABLE 69. CNANO TECHNOLOGY: PRODUCTS & SERVICES
TABLE 70. CNANO TECHNOLOGY: RECENT DEVELOPMENTS
TABLE 71. DONAU CHEMIE GROUP: FINANCIALS
TABLE 72. DONAU CHEMIE GROUP: PRODUCTS & SERVICES
TABLE 73. DONAU CHEMIE GROUP: RECENT DEVELOPMENTS
TABLE 74. SHOWA DENKO: FINANCIALS
TABLE 75. SHOWA DENKO: PRODUCTS & SERVICES
TABLE 76. SHOWA DENKO: RECENT DEVELOPMENTS